Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...
News Medical on MSN2d
Affordability and supply remain critical to the success of long-lasting HIV drugAffordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Called pre-exposure prophylaxis (PrEP), this is ... it’s not yet approved for HIV prevention by medical regulators. The drug is currently priced at around US$42,000 (£31,600) a year if used ...
In the last 30 years, HIV rates have gone down, in large part because of the game-changing prescription drug pre-exposure ...
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
Lenacapavir for PrEP, injected just under the skin every ... which introduced the first long-acting HIV-prevention drugs but has not delivered a drug with the extended protection of lenacapavir.
The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...
Long-acting PrEP like CAB LA is a game-changer for ... ViiV Healthcare is ramping up its supply of an important HIV prevention drug to help reduce infections in the places that need it most ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback